Format

Send to

Choose Destination
J Comp Eff Res. 2015 May;4(3):279-286. doi: 10.2217/cer.15.10. Epub 2015 May 11.

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.

Author information

1
University Hospital Llandough, Penlan Road, Penarth, Cardiff CF64 2XX, UK.
2
Swansea Centre for Health Economics, University of Swansea, Singleton Park, Swansea, UK.

Abstract

The increasing prevalence of diabetes presents one of the greatest challenges to healthcare provision in modern times, with the cost of treating diabetes and its related complications representing a significant proportion of healthcare expenditure. In recent years, many new therapeutic entities have been developed with the aim of improving glycemic control, and thus slowing the development of micro- and macrovascular complications. Insulin degludec is a new-generation basal insulin analog with an ultra-long duration of action and low day-to-day and hour-to-hour intrapatient variability in blood glucose-lowering action. In this review, we consider evidence from clinical trials and real-world studies demonstrating the clinical benefits and cost-effectiveness of insulin degludec and its potential for improving patient care.

KEYWORDS:

analog; cost–effectiveness; diabetes; flexible dosing; hypoglycemia; insulin degludec; real-world studies

PMID:
25959645
DOI:
10.2217/cer.15.10
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center